In a recent interview, Andrea Pezzella, MD, URPS, FACOG, of Southern Urogynecology Wellness & Aesthetics in West Columbia, South Carolina, shared insights on Neuspera’s innovative integrated sacral ...

Panelists discuss the critical unmet need for more personalized treatment in non–muscle-invasive bladder cancer (NMIBC), emphasizing the role of biomarkers, emerging modalities like radiation, and ...

Howard B. Goldman, MD, who was the first to use the device in a clinical setting, shares his initial thoughts on the technology and its role in real-world practice.

Key Takeaways The Co-PSMA trial compares 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT for detecting prostate cancer recurrence post-radical prostatectomy. 64Cu-SAR-bisPSMA has received FDA fast track ...

In this video, Bridget Lang Findlay, MD, a reconstructive urologist with Mayo Clinic in Phoenix, Arizona, focuses on her study examining long-term bladder management strategies among women with spinal ...

The FDA and the French National Agency for the Safety of Medicines and Health Products (ANSM) have granted an investigational device exemption (IDE) clearance to a pivotal trial of the UroActive smart ...

Data showed that African American men faced significant delays in treatment initiation. A recent analysis demonstrated that although African American men and non-African American men had comparable ...

BCAN's $1 million Continuity Grant supports bladder cancer research projects impacted by federal funding terminations, ensuring continued progress in the field. Eligible projects include basic, ...

A panelist discusses how different abiraterone formulations require specific steroid combinations—prednisone with traditional abiraterone and prednisolone with microformulation—and the importance of ...

Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...